Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBNX Beta Bionics	$14.67 +4.5%	$0.00	$13.64 ▼ $24.50	$628.74M	N/A	367,656 shs	269,381 shs
CATX Perspective Therapeutics	$2.59 -1.1%	$3.14	$2.32 ▼ $19.05	$175.05M	1.25	801,410 shs	394,970 shs
IRMD Iradimed	$52.45 +2.0%	$57.09	$40.18 ▼ $63.29	$666.90M	0.83	41,193 shs	31,240 shs
SIBN SI-BONE	$14.75 +0.3%	$16.54	$11.70 ▼ $19.16	$626.18M	1.17	356,069 shs	183,199 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBNX Beta Bionics	+4.49%	-9.11%	-33.29%	+1,466,999,900.00%	+1,466,999,900.00%
CATX Perspective Therapeutics	-1.15%	-0.77%	-14.52%	-25.57%	+258,999,900.00%
IRMD Iradimed	+1.96%	+0.46%	-13.28%	-0.34%	+16.56%
SIBN SI-BONE	+0.27%	-8.16%	-9.06%	+9.91%	-9.06%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	3.099 of 5 stars	4.6	0.0	0.0	0.0	2.7	0.8	0.6
IRMD Iradimed	4.8553 of 5 stars	3.5	2.0	2.5	4.4	3.3	3.3	1.9
SIBN SI-BONE	4.1353 of 5 stars	3.5	3.0	0.0	3.3	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBNX Beta Bionics	2.78	Moderate Buy	$24.83	69.28% Upside
CATX Perspective Therapeutics	3.17	Buy	$14.56	461.99% Upside
IRMD Iradimed	3.00	Buy	$72.00	37.27% Upside
SIBN SI-BONE	3.00	Buy	$24.50	66.10% Upside

Current Analyst Ratings Breakdown

Latest CATX, IRMD, SIBN, and BBNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/13/2025	CATX Perspective Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/10/2025	CATX Perspective Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/7/2025	CATX Perspective Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/6/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/4/2025	CATX Perspective Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/25/2025	SIBN SI-BONE	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $22.00
2/25/2025	SIBN SI-BONE	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
2/25/2025	SIBN SI-BONE	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $24.00
2/24/2025	BBNX Beta Bionics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/24/2025	BBNX Beta Bionics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
2/24/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 3/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBNX Beta Bionics	$53.03M	11.86	N/A	N/A	N/A	∞
CATX Perspective Therapeutics	$1.43M	122.41	N/A	N/A	$2.67 per share	0.97
IRMD Iradimed	$73.24M	9.11	$1.31 per share	40.12	$5.66 per share	9.27
SIBN SI-BONE	$167.18M	3.75	N/A	N/A	$4.18 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBNX Beta Bionics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	3/26/2025 (Estimated)
IRMD Iradimed	$19.23M	$1.50	34.97	26.23	N/A	26.26%	24.12%	21.20%	5/1/2025 (Estimated)
SIBN SI-BONE	-$43.34M	-$0.76	N/A	N/A	N/A	-23.82%	-22.51%	-16.53%	5/5/2025 (Estimated)

Latest CATX, IRMD, SIBN, and BBNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/26/2025	N/A	CATX Perspective Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
2/24/2025	Q4 2024	SIBN SI-BONE	-$0.16	-$0.11	+$0.05	-$0.11	$48.87 million	$49.00 million
2/13/2025	Q4 2024	IRMD Iradimed	$0.45	$0.40	-$0.05	$0.40	$19.09 million	$19.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
IRMD Iradimed	$0.68	1.30%	N/A	45.33%	N/A
SIBN SI-BONE	N/A	N/A	N/A	N/A	N/A

Latest CATX, IRMD, SIBN, and BBNX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	IRMD Iradimed	quarterly	$0.17	1.1%	2/24/2025	2/24/2025	3/5/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBNX Beta Bionics	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	9.60	9.60
IRMD Iradimed	N/A	9.21	7.82
SIBN SI-BONE	0.22	8.25	7.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBNX Beta Bionics	N/A
CATX Perspective Therapeutics	54.66%
IRMD Iradimed	92.34%
SIBN SI-BONE	98.11%

Insider Ownership

Company	Insider Ownership
BBNX Beta Bionics	N/A
CATX Perspective Therapeutics	3.52%
IRMD Iradimed	37.10%
SIBN SI-BONE	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBNX Beta Bionics	294	42.86 million	N/A	N/A
CATX Perspective Therapeutics	70	67.59 million	65.21 million	Optionable
IRMD Iradimed	110	12.72 million	7.97 million	Optionable
SIBN SI-BONE	350	42.45 million	40.30 million	Optionable

CATX, IRMD, SIBN, and BBNX Headlines

Recent News About These Companies

SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Victory Capital Management Inc.

March 15 at 3:27 AM | marketbeat.com

SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Essex Investment Management Co. LLC

March 10, 2025 | marketbeat.com

How SI-BONE, Inc. (NASDAQ:SIBN) Continues to Perform Despite Fluctuating Market Support

March 8, 2025 | kalkinemedia.com

SI-BONE, Inc. (NASDAQ:SIBN) Receives $24.50 Consensus Target Price from Brokerages

March 8, 2025 | americanbankingnews.com

SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by New York State Common Retirement Fund

March 6, 2025 | marketbeat.com

SI-BONE, Inc. 2024 Q4 - Results - Earnings Call Presentation

March 4, 2025 | seekingalpha.com

SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Rating of "Buy" from Analysts

March 3, 2025 | marketbeat.com

VELA Investment Management LLC Boosts Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

March 1, 2025 | marketbeat.com

SI-BONE FY2025 EPS Forecast Decreased by Cantor Fitzgerald

February 28, 2025 | marketbeat.com

Q4 2024 SI-BONE Inc Earnings Call

February 26, 2025 | uk.finance.yahoo.com

SI-BONE (NASDAQ:SIBN) Reaches New 1-Year High on Analyst Upgrade

February 26, 2025 | marketbeat.com

Bank of America Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)

February 25, 2025 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on SI-Bone (SIBN)

February 25, 2025 | markets.businessinsider.com

SI-BONE, Inc. (NASDAQ:SIBN) Q4 2024 Earnings Call Transcript

February 25, 2025 | msn.com

Truist Financial Reiterates "Buy" Rating for SI-BONE (NASDAQ:SIBN)

February 25, 2025 | marketbeat.com

SI-BONE (NASDAQ:SIBN) Shares Gap Up After Better-Than-Expected Earnings

February 25, 2025 | marketbeat.com

SI-BONE (NASDAQ:SIBN) Receives "Overweight" Rating from Cantor Fitzgerald

February 25, 2025 | marketbeat.com

Needham & Company LLC Forecasts Strong Price Appreciation for SI-BONE (NASDAQ:SIBN) Stock

February 25, 2025 | marketbeat.com

SI-Bone reports Q4 EPS (11c), consensus (13c)

February 25, 2025 | markets.businessinsider.com

SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript

February 25, 2025 | seekingalpha.com

SI-Bone sees FY25 revenue $193.5M-$195.5M, consensus $193.47M

February 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CATX, IRMD, SIBN, and BBNX Company Descriptions

Beta Bionics NASDAQ:BBNX

$14.67 +0.63 (+4.49%)

As of 03/14/2025 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Perspective Therapeutics NYSE:CATX

$2.59 -0.03 (-1.15%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$2.60 +0.01 (+0.19%)

As of 03/14/2025 07:07 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Iradimed NASDAQ:IRMD

$52.45 +1.01 (+1.96%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$52.38 -0.08 (-0.14%)

As of 03/14/2025 04:05 PM Eastern

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

SI-BONE NASDAQ:SIBN

$14.75 +0.04 (+0.27%)

Closing price 03/14/2025 04:00 PM Eastern

Extended Trading

$14.72 -0.03 (-0.17%)

As of 03/14/2025 04:33 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time